Abstract
Malignant melanoma is the most aggressive cutaneous malignancy with dismal prognosis in the advanced setting. The food and drug administration approval of ipilimumab, the monoclonal antibody against cytotoxic T-lymphocyte antigen 4, has significantly changed treatment strategies for this disease. However, the spectrum of immune-related adverse events secondary to ipilimumab therapy is a growing area of research, and clinical observations of rare immune events as a result of such therapies continue to be reported since the approval. The co-occurrence of disease progression along with an immune-related adverse event is extremely rare. We here present the first case, to our knowledge, of diffuse nonnecrotizing granulomatous lymphadenopathy occurring simultaneously with disease progression in a patient with metastatic melanoma after receiving the second dose of ipilimumab.
Original language | English (US) |
---|---|
Pages (from-to) | e1068-e1071 |
Journal | American Journal of Therapeutics |
Volume | 23 |
Issue number | 4 |
DOIs | |
State | Published - Aug 1 2016 |
Externally published | Yes |
Keywords
- Granuloma
- Ipilimumab
- Metastatic melanoma
- Nonnecrotizing
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)